

Tuvusertib


Chemical Properties

CAS No. : 1613200-51-3

Formula: C₁₆H₁₂F₂N₈O

Molecular Weight: 370.32

Storage: Store at low temperature, Keep away from direct sunlight, Keep away from moisture
 Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.



Biological Description

Description	Tuvusertib (M1774) is an orally available ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor ($K_i < 1 \mu\text{M}$) with selective and potentially antitumor activity. Tuvusertib selectively inhibits ATR activity and blocks downstream phosphorylation of serine/threonine protein kinase checkpoint kinase 1 (CHK1), thereby inhibits DNA damage checkpoint activation, disrupting DNA damage repair and inducing apoptosis in tumor cells.
Targets(IC50)	Apoptosis, ATM/ATR, Chk

Solubility Information

Solubility	DMSO: 6.67 mg/mL (18.01 mM), Sonication is recommended. ($< 1 \text{ mg/ml}$ refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 0.67 mg/mL (1.81 mM), Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.7004 mL	13.5018 mL	27.0037 mL
5 mM	0.5401 mL	2.7004 mL	5.4007 mL
10 mM	0.270 mL	1.3502 mL	2.7004 mL
50 mM	0.054 mL	0.270 mL	0.5401 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Nadia AHMAD, et al. Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a] pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof. WO2015187451A1.

Alimzhanov, et al. Combination of a PD-1 antagonist, an ATR kinase inhibitor and a platinating agent for the treatment of cancer. WO2020064971 A1.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481